Abpro

Abpro Corporation is a biotechnology company dedicated to developing next-generation antibody therapeutics to improve severe and life-threatening diseases. The company initially focuses on novel antibody constructs for immuno-oncology, ophthalmology, and autoimmune diseases. By leveraging their proprietary DiversImmune and MultiMab antibody discovery and engineering platforms, the company is independently developing a series of potentially best-in-class antibodies and collaborating with global pharmaceutical and research institutions.